[{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"}]